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Backgrounds/Aims: Approximately 60-80% of patients with intrahepatic cholangiocarcinoma (iCCA) are not suitable for 
surgical resection due to advanced disease at presentation. This review assesses the role of surgical resection followed 
by down staging treatment in the management of patients with locally advanced iCCA. Methods: A systematic review 
and pooled analysis were performed of the relevant published studies published between January 2000-December 
2018. The primary outcome measure was overall survival. Secondary outcome measures were rates of clinical benefit, 
margin-negative (R0) resections, overall and surgery-specific complications, and post-operative mortality. Results: 
Eighteen cohort studies with 1880 patients were included in the review. The median overall survival in all patients 
was 14 months (range, 7-18 months). Patients undergoing resection following down staging had significantly longer 
survival than those who did not (median: 29 vs. 12 months, p＜0.001). The Clinical Benefit Rate with this strategy 
(complete response+partial response+stable disease) was 64% (244/383), ranging from 33-90%. Thirty-eight percent 
of the patients underwent resections with a 60% R0 resection rate and 6% postoperative mortality. Conclusions: 
Although the evidence to support the benefits of NAT for iCCA is limited, the review supports the use of down staging 
treatment and also surgical resection in the cohort with response to NAT in order to improve long-term survival in 
patients with locally advanced iCCA. (Ann Hepatobiliary Pancreat Surg 2020;24:6-16)
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INTRODUCTION
The incidence of intrahepatic cholangiocarcinoma (iCCA) 
is about 0.7 cases per 100,000 adults in the USA.1 Despite 
advances in multimodality treatment, long-term survival is 
only seen in 10-20% of patients due to the advanced stage 
at presentation.2 Surgical resection remains the only po-
tentially curative therapy for patients with iCCA; how-
ever, only 30-60% of patients are candidates for surgical 
resection due to locally advanced (large tumors with ei-
ther hepatic inflow or outflow involvement) or metastatic 
disease, underlying chronic liver disease, or frailty.3 In pa-
tients undergoing surgical resection, the 5-year survival is 
20-40%, and median survival is 25 months.3 
In patients with unresectable disease, median survival 
is 12-15 months with a 5-year survival of 5-10%,4,5 with 
chemotherapy based on a combination of gemcitabine and 
platinum salts.6 There is no established standard treatment 
for patients with locally advanced biliary cancers. The 
role of chemotherapy or radiotherapy is considered mainly 
a palliative in unresectable iCCA. Neoadjuvant therapy 
(NAT) with a view to downstage has gained popularity 
in the last decade in the management of hepatobiliary and 
pancreatic cancers, particularly the latter in patients with 
borderline resectable and locally advanced (LA) cancers. 
Pooled analysis by Suker et al.7 in a systematic review 
demonstrated NAT with FOLFIRINOX for locally advan-
ced pancreatic cancers had a median overall survival (OS) 
ranging between 10 and 33 months and resection rates of 
up to 43%. In resectable oesophageal cancers, NAT has 
Sivesh Kamarajah, et al. Down staging of locally advanced intrahepatic cholangiocarcinoma  7
been demonstrated standard treatment through high-qual-
ity randomized controlled trials.8 A recent network meta- 
analysis further demonstrated neoadjuvant CRT (chemora-
diotherapy) followed by surgery to be the most effective 
strategy in improving long-term survival of resectable oe-
sophageal cancers.9
To date, there is limited consensus for advocating NAT 
for patients with iCCA to further improve survival and 
surgical outcomes. For the purpose of the study, this was 
considered downstaging treatment given to patients with 
non-metastatic iCCA as NAT, although the intention 
might have been palliation given the clinical practice dur-
ing the study period. Hence, the aim of this review is to 
determine the oncological and surgical outcomes of pa-
tients receiving NAT for borderline iCCA. 
METHODS
Search strategy
A systematic search of PubMed, EMBASE and the 
Cochrane Library databases were conducted. The search 
terms used were ‘intrahepatic cholangiocarcinoma’ or ‘chol-
angiocarcinoma’, and ‘neoadjuvant therapy or ‘neoadjuvant 
radiotherapy’ or ‘neoadjuvant chemotherapy’ or ‘chemothe-
rapy’ individually or in combination. Search terms used 
for this review are presented as shown in Supplementary 
Table 1. The ‘related articles’ function was used to broad-
en the search, and all citations were considered for re-
levance. A manual search of reference lists in recent re-
views and eligible studies was also undertaken. 
Inclusion and exclusion criteria
Inclusion criteria were: (1) studies reporting the use of 
NAT (by any modality) in human subjects with non-meta-
static locally advanced iCCA; (2) published in the English 
language. Exclusion criteria were: (1) conference ab-
stracts, review articles, and case reports (<5 patients); (2) 
publications with mixed populations where the outcomes 
of patients with cancers at another site could not be sepa-
rated from those of patients with intrahepatic cholan-
giocarcinoma. After excluding duplicates, two authors 
(SK, BD) independently reviewed the titles and abstracts 
of studies identified by the literature search. Where a 
study was considered to be potentially relevant to the re-
search question a full copy of the publication was ob-
tained for further review. The references of all included 
studies were hand-searched in order to identify other po-
tentially relevant studies. Any areas of disagreement be-
tween the two primary researchers were resolved through 
discussion. The intention of the NAT in this review might 
have been palliative treatment when offered to patients 
but patients have then progressed to surgical pathways 
where response has been noted. It is therefore important 
to note the differences in the terminology used in this re-
view to the terms used in standard clinical practice. 
Patients who progressed to surgery following down stag-
ing treatment are considered to have had surgery follow-
ing NAT, patients who received treatment but not surgery 
had palliative chemotherapy, and those who did not re-
ceive any treatment (no NAT group) were managed by 
best supportive care.
Data extraction
Two researchers (SK, BD) independently extracted data 
on study characteristics, patient demographics, definitions 
of borderline resection, modality and regimes of NAT, re-
sponse to and the clinical benefit with NAT, progression 
to surgery and postoperative outcomes such as overall 
mortality and morbidity rates such as bile leak, liver fail-
ure, where reported.
Study outcomes
The primary outcome measure was OS in patients re-
ceiving NAT with or without subsequent surgical resec-
tion. Response to chemotherapy, where reported, was grad-
ed as complete response (CR), partial response (PR), sta-
ble disease (SD), and progressive disease (PD). Secondary 
outcome measures were rates of overall resection rates 
and margin-negative (R0) resections, overall complica-
tions (Grade I-V) and major complications (＞Grade III) 
reported according to Clavien-Dindo classification, sur-
gery-specific complications (bile leak, intra-abdominal 
collections), and response to chemotherapy. A pooled 
analysis of the data was performed to assess the study 
outcomes and a comparative survival analysis was per-
formed. 
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RESULTS
Study characteristics
The literature search identified 18 cohort studies, in-
cluding 1880 patients with locally advanced iCCA, of 
which two were prospective cohort studies. Baseline dem-
ographics of the included studies are presented in Table 1. 
Study quality was assessed using NewCastle Ottawa 
system. Ten studies provided the definitions for locally 
advanced or inoperable iCCA, and these are detailed in 
Table 2. 
Chemotherapy and radiotherapy regimes 
NAT regimes and tumor responses are presented in 
Table 3. Eleven studies reported the use of neoadjuvant 
chemotherapy, of which four10,11,14,15 reported the use of 
transarterial chemoembolization (TACE) with mitomycin 
C (MMC). One study14 used gemcitabine and cisplatin in 
addition to MMC for TACE. Eight studies5,12,17-20,22,26 
evaluated combinations of chemotherapy (gemcitabine/ca-
pecitabine and platinum-based regimes). Of the remaining 
studies, one reported use of RT,13 three reported use of 
chemoradiotherapy (CRT),16,23,25 and one compared con-
current CRT, chemotherapy and RT, chemotherapy, and 
no treatment.24
Response rates and the definitions of response
Eleven studies reported the criteria used to assess tu-
mour response [RECIST (n=9),10,11,14,16,17,19,21,23,25 mRECIST 
(n=1),5 and WHO (n=1)].12 Nine studies5,10-14,16,17,25  (n=383 
patients) provided response rates as the presence of pro-
gressive disease (PD), stable disease (SD), partial re-
sponse (PR), and complete response (CR). The rates of 
PD were 36%, ranging from 10 to 67%. The Clinical 
Benefit Rate (CBR=CR+PR+SD) was noted in 64% 
(244/383) of the patients going for NAT, ranging from 33 
to 90%. 
Resectability rates
Of the nine studies5,10-14,16,17,25 (383 patients) where re-
sponse rates were provided, 64% (244/383) showed a clin-
ical benefit for NAT. None of the studies provided the 
number of patients who were explored for but failed to 
proceed to resection following NAT. Of the studies5,17,19-22,25,26 
where post-NAT resection rates were reported, 135/354 
patients (38%) underwent resections. Of these, 60% of the 
patients had R0 resections (82/135 patients), 40% were re-
ported to have R1 resection, and R2 resection was per-
formed in 1/135 patients.
Overall survival 
The OS of the entire cohort was 14 months (range, 7-18 
months). OS was significantly longer in patients receiving 
NAT with resection (median: 29 months; range: 18-37 
months) compared to NAT alone (median: 12 months; 
range: 5-43 months) or no NAT (median: 8 months; range: 
5-11 months) (p＜0.001) for locally advanced iCCA. In 
patients receiving chemotherapy only, the OS of the entire 
cohort was 18 months (range, 5-20 months). OS was sig-
nificantly longer in patients receiving NAT with resection 
(median, 36 months; range, 18-37 months) compared to 
NAT alone (median, 12 months; range, 5-43 months, 
p=0.02). In patients receiving CRT only, the OS of the 
entire cohort was 12 months (range, 9-15 months). OS 
was longer in patients receiving NAT with resection 
(median, 21 months; range, 18-24 months) compared to 
NAT alone (median: 11 months; range: 9-43 months, 
p=0.8) (Table 4). 
Postoperative outcomes
Overall post-surgical complications were reported in 
eight studies.5,17,19-22,25,26 The overall rate of postoperative 
mortality was 6% (8/135 patients) on pooled analysis. The 
rate of major complications was 15.5% (21/135 patients). 
Bile leaks (four patients), post-hepatectomy liver failure 
(four patients), intraabdominal collections (four patients), 
ascites (three patients), post-operative bleeding (one pa-
tient), pleural effusion (one patient), and acute kidney in-
jury (one patient) were the reported complications (Table 
5). 
DISCUSSION
Over the last decade, the long-term survival of patients 
diagnosed with iCCA has been relatively poor, with a 
small proportion of patients undergoing curative surgical 
resection and a median survival of 20-30 months in the 
resected group.3 NAT for iCCA is an appealing option for 
suitable candidates to select the patient with less ag-
gressive tumor biology, downstage the disease, increase 
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Table 4. Overall survival among the patients in the all the treatment pathways
Study name All patients, n OS entire cohort, months
OS NAT+ 
resection, months
OS NAT only, 
months
OS no NAT, 
months
Herber et al. 200710 15 21 (9-33) - 21 (9-33) NR
Shitara et al. 200811 20 14 - 14 NR
Nehls et al. 200812 18 NR - NR NA
Chen et al. 201013 84 7±1 - 10±1 5±1
Vogl et al. 201214 115 13 - 13 NA
Scheuermann et al. 201315 32 NR - 11 NR
Kim et al. 201316 132 9 - 9 NR
Kato et al. 201317 7 13 29 13 NA
Yi et al. 201418 176 NR - 43 (34-51) 11 (7-16)
Kato et al. 201519 25 NR NR NR NR
Rayar et al. 201520 45 NR 16 (4-41) NR NR
Konstantinidis et al. 201621 167 20 (1-120) 37 (10-92) NR NR
Omichi et al. 201722 43 NR NR NA NA
Cho et al. 201723 64 NR NR NR NR
Chang et al. 201824 844 NR - NR NR
Sumiyoshi et al. 201825 7 NR NR NR NR
Lunsford et al. 201826 12 NR 36 NR NR
Le Roy et al. 20185 74 18 36 11 NA
Table 5. Post-operative outcomes following resection surgery, where reported
Numbers 
received NAT
Numbers 
proceeded to 
resection
R0 resection R1 resection Post-op mortality Major morbidity 
Kato et al. 201519 39 10 7 3 - -
Kato et al. 201317 22 8 4 4 - -
Rayar et al. 201520 45 10 10 0 2 3
Konstantinidis et al. 201621 104 8 5 3 2
Sumiyoshi et al. 201825 15 11 9 2 - 3
Omichi et al. 201722 43 43 30 13 - 5
Lunsford et al. 201826 12 6 5 1 - 1
Le Roy et al. 20185 74 39 12 27 4 9
Total 354 135 (38.1%) 82 (60.7%) 53 (39.2%) 8 (6%) 21 (15.5%)
the resectability rates, and improve the OS in the locally 
advanced iCCA. NAT therapy in iCCA lags behind other 
gastrointestinal cancers, such as oesophageal and pancre-
atic cancers, where this approach has shown significant 
improvement in long term-survival and increased the 
number of ongoing clinical trials.7,9 The present review 
highlights that current evidence for NAT in iCCA is lim-
ited to cohort studies, specifically retrospective case 
series. This review further highlights that NAT followed 
by resection has a superior survival rate than patients re-
ceiving NAT alone or no surgery in the group of patients 
deemed unresectable because of locally advanced disease. 
Le Roy et al.5 reported no significant difference in the pa-
tients who had primarily resectable and downstaged un-
resectable lesions in terms of postoperative complications, 
but despite the higher R1 resection rates (p=0.004), the 
OS was similar (HR 1.23, 0.77–1.97; p=0.391) between 
the two groups. The current review does not differentiate 
the outcomes of R1 and R0 resections but together the 
OS was significantly better in the cohort that proceeded 
for surgery following downstaging NAT.
iCCAs are usually peripherally located, away from the 
hilum and are usually dealt with by anatomical, non-ana-
tomical resections based on the position of the lesion. 
When the lesions are larger or located centrally, the in-
flow or (more often) the outflow of the liver could be 
infiltrated. Such vascular or biliary involvement on the 
contralateral side of resection are usually considered the 
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limiting factor for upfront resection.25 The group of pa-
tients with iCCA that is not suitable for surgical resections 
are usually put through a palliative pathway or best sup-
portive care. Factors such as micro or macro vascular in-
vasion, presence of lymph node metastases, and presence 
of satellite nodules represent poor pathological prognostic 
factors. The influence of pathological factors on their out-
comes is not clear from this review. However, this study 
has shown a variable median OS in the group of patients 
receiving NAT (with or without curative resection) with 
an encouraging survival benefit. There is a lack of a defi-
nition for locally advanced iCCA, which might reflect the 
lack of consensus about the patients suitable for NAT and 
type of treatment in the context of multimodal treatment 
options (Table 2). We propose that the HPB surgical com-
munity should aim to obtain consensus for the definition 
of borderline resectability and selection of iCCA patients 
for NAT. In this group of patients, NAT might be able 
to increase resectability rates, with acceptable morbidity, 
mortality, and prolonged survival.
The response rates of iCCA to chemotherapy are varia-
ble and limited. Currently, there is no standard treatment 
for locally advanced cholangiocarcinoma, either in a NAT 
or palliative set up. The ABC-02 trial compared doublet 
therapy with gemcitabine and cisplatin to gemcitabine as 
a single agent in 410 patients with locally advanced or 
metastatic biliary tract cancer.6 After a median follow-up 
of 8.2 months, the combination group had a significantly 
improved OS (11.7 vs. 8.1 months). Similar results with 
combination chemotherapy were also reported by studies 
with a 70% response rate or stable disease and OS of up 
to 15 months.27 The results of ABC06 trial for 2nd line 
chemotherapy with FOLFOX regime are awaited but the 
unpublished results are promising.28 Other treatment op-
tions, such as chemoradiotherapy, TACE, and external 
beam RT, have also been associated with longer pro-
gression-free survival and OS than chemotherapy alone in 
a palliative setting for patients with unresectable advanced 
iCCA.29 Shitara et al.11 reported a 50% response rate and 
a median survival of 14.1 months with hepatic arterial in-
fusion chemotherapy for unresectable iCCA. The review 
also reflects the variations in the NAT regimes used by 
the included studies, although the majority of studies used 
a gemcitabine-based chemotherapy regime and only one 
study used a standardized regime (gemcitabine/oxaliplatin) 
in all patients. Other limitations to this study include sig-
nificant heterogeneity of the included studies with no 
clear definitions of locally advanced iCCA. Not all of the 
reported studies reported the survival data, and well-de-
fined post-operative complications, limiting the quality of 
the meta-analysis to reliably analyze the impact of NAT 
in patients with and without surgical resection. However, 
the current study provides the base to plan future studies 
that would be of useful in the management of this group 
of patients.
In conclusion, although the evidence to support the 
benefits of NAT for iCCA is limited, the data from this 
review is very promising in improving the outcomes of 
patients with iCCA. International efforts are required to 
standardize the definitions and treatment regimens target-
ing locally advanced iCCA through randomized controlled 
trials. 
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